Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Viracta Therapeutics Inc (VIRX)

Viracta Therapeutics Inc (VIRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Viracta Therapeutics Inc 2533 S. COAST HWY. 101 SUITE 210 CARDIFF CA 92007 USA

www.viracta.com P: 858-400-8470

Description:

Viracta Therapeutics Inc. is a precision oncology company targeting virus-associated malignancies. The company is pursuing application of inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma and other virus-related cancers. Viracta Therapeutics Inc., formerly known as Sunesis Pharmaceuticals Inc., is based in SAN DIEGO.

Key Statistics

Overview:

Market Capitalization, $K 32,843
Enterprise Value, $K 51,243
Shares Outstanding, K 39,272
Annual Sales, $ 0 K
Annual Net Income, $ -51,060 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -13,770 K
EBIT, $ -50,700 K
EBITDA, $ -52,260 K
60-Month Beta 0.93
% of Insider Shareholders 7.42%
% of Institutional Shareholders 31.37%
Float, K 36,358
% Float 92.58%
Short Volume Ratio 0.19

Growth:

1-Year Return -35.83%
3-Year Return -92.26%
5-Year Return -98.26%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 94.97%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.35 on 03/07/24
Latest Earnings Date 05/13/24
Earnings Per Share ttm -1.32
EPS Growth vs. Prev Qtr -6.06%
EPS Growth vs. Prev Year -29.63%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-7 on 02/25/21

VIRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -172.32%
Return-on-Assets % -71.40%
Profit Margin % 0.00%
Debt/Equity 1.38
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.64
Book Value/Share 0.47
Interest Coverage -12.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar